4.8 Article

Atomic structure of a toxic, oligomeric segment of SOD1 linked to amyotrophic lateral sclerosis (ALS)

Publisher

NATL ACAD SCIENCES
DOI: 10.1073/pnas.1705091114

Keywords

oligomer; SOD1; ALS

Funding

  1. Howard Hughes Medical Institute, Department of Energy
  2. National Institutes of Health (NIH) [AG029430]
  3. University of California, Los Angeles (UCLA) Broad Center of Regenerative Medicine and Stem Cell Research
  4. Rose Hills Foundation
  5. National Institute of Neurological Disorders and Stroke [NS072804]
  6. Muscular Dystrophy Association [92901]
  7. California Institute for Regenerative Medicine (CIRM) [RB1-01367, RB5-07480]
  8. CIRM [RT307678]
  9. National Institute of General Medical Sciences [GM61721]
  10. NIH [AG047116]
  11. National Science Foundation [CHE-1301032, CHE-1565941]
  12. Whitcome Pre-Doctoral fellowship
  13. UCLA Cellular and Molecular Biology Training program (Ruth L. Kirschstein NIH Grant) [GM007185]
  14. UCLA-California Institute for Regenerative Medicine Training Grant
  15. UCLA Graduate Division Dissertation Year Fellowship
  16. Larry L. Hillblom Foundation Fellowship
  17. Beckman Research Scholarship
  18. Division Of Chemistry
  19. Direct For Mathematical & Physical Scien [1301032] Funding Source: National Science Foundation

Ask authors/readers for more resources

Fibrils and oligomers are the aggregated protein agents of neuronal dysfunction in ALS diseases. Whereas we now know much about fibril architecture, atomic structures of disease-related oligomers have eluded determination. Here, we determine the corkscrew-like structure of a cytotoxic segment of superoxide dismutase 1 (SOD1) in its oligomeric state. Mutations that prevent formation of this structure eliminate cytotoxicity of the segment in isolation as well as cytotoxicity of the ALS-linked mutants of SOD1 in primary motor neurons and in a Danio rerio (zebrafish) model of ALS. Cytotoxicity assays suggest that toxicity is a property of soluble oligomers, and not large insoluble aggregates. Our work adds to evidence that the toxic oligomeric entities in protein aggregation diseases contain antiparallel, out-of-register beta-sheet structures and identifies a target for structurebased therapeutics in ALS.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available